You have 9 free searches left this month | for more free features.

Condition

Diffuse Large B-cell Lymphoma Recurrent (2)

DLBCL (1)

Diffuse Large B Cell Lymphoma Refractory (1)

Diffuse Large B-cell Lymphoma Refractory (1)

Overall Status

Completed (1)

Not yet recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (1)

phase 2 (1)

phase 2/phase 3 (1)

Sponsor

Fondazione Italiana Linfomi - ETS (1)

Fondazione Italiana Linfomi ONLUS (1)

Stichting Hemato-Oncologie voor Volwassenen Nederland (1)

Collaborator

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte (1)

Janssen Pharmaceutica (1)

Janssen-Cilag Ltd. (1)

Roche Pharma AG (1)

Intervention

r-dhap (3)

br-dhap (1)

brentuximab vedotin (1)

pola-r-dhap (1)

Study Documents

Intervention Type

drug (3)

combination product (1)

Funder Type

Other (3)

Study Type

Interventional (3)

r-dhap

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent Trial in Italy (R-DHAP, Pola-R-DHAP)

Not yet recruiting

Diffuse Large B Cell Lymphoma Refractory
Diffuse Large B-cell Lymphoma Recurrent

R-DHAP
Pola-R-DHAP

Alessandria, Italy
+39 more

Jul 28, 2023

Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent Trial in Italy (R-DHAP, BR-DHAP)

Completed

Diffuse Large B-cell Lymphoma Refractory
Diffuse Large B-cell Lymphoma Recurrent

R-DHAP
BR-DHAP

Meldola, Forlì-Cesena, Italy
+23 more

Nov 26, 2021

DLBCL Trial in Rotterdam (R-DHAP, Brentuximab Vedotin)

Recruiting

DLBCL

R-DHAP
Brentuximab Vedotin

Rotterdam, Netherlands

NL-Rotterdam-ERASMUSMC

Dec 9, 2020